Sangamo Therapeutics Bankruptcy & Restructuring
Sangamo Therapeutics, Inc. filed a monthly operating report (MOR) for August 2026 as part of its ongoing Chapter 11 bankruptcy proceedings in the District of Delaware. The report discloses a month-end cash balance of $23.2 million and total liabilities of $107.3 million. Additionally, the company's common stock is being delisted from Nasdaq effective October 17, 2026, following its suspension in May 2026.